Studies related to the administration of vitamin D3 to MS patients have reduced the mRNA expression levels of the proinflammatory cytokines IL-17A and IL-6 and increased the mRNA expression levels of the anti-inflammatory interleukin IL-10 [126]. Here, IL17A is linked to myeloid sarcoma.